



CURRICULUM VITAE of Dr. Yu Yuanyuan (yu.yy01@hotmail.com)

Name: Yu Yuanyuan

Academic qualifications:

2003.9-2007.7	Bachelor of Science	School of Biotechnology, Weifang University, P. R. China
2007.9-2010.7	Master of Science	Department of Microbiology, Liaoning University, P. R. China
2010.9-2015.2	Doctor of Philosophy	Department of Biochemistry, Faculty of Medicine, The University of Hong Kong, Hong Kong S.A.R

Present academic position:

2015.11-	Postdoctoral Research Fellow	Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University
----------	------------------------------	---

Previous relevant research work:

Research area Nucleic acid aptamer selection and characterization

Representative publications

1. **Yu, Y.**, Chan, D., Cheah, K.S.E & Tanner, J.A. Nucleic acid aptamers against aggrecanases: a novel method for degenerative disc disease therapy. *ChemBioChem*, under review.
2. **Yu, Y.**, Liu, X., He, J., Zhang, M., Li, H., Wei, D., and Song, Y. (2012) Appendant structure plays an important role in amyloidogenic cystatin dimerization prior to domain swapping, *J Biomol Struct Dyn*30, 102-112.
3. Shen, M., Guan, J., Xu, L., **Yu, Y.**, He, J., Jones, G. W., and Song, Y. (2012) Steered molecular dynamics simulations on the binding of the appendant structure and helix-beta2 in domain-swapped human cystatin C dimer, *J Biomol Struct Dyn*30, 652-661.
4. **Yu, Y.**, Wang, Y., He, J., Liu, Y., Li, H., Zhang, H., and Song, Y. (2010) Structural and dynamic properties of a new amyloidogenic chicken cystatin mutant I108T, *J Biomol Struct Dyn*27, 641-649.
5. **Yu, Y.** & Tanner, J.A. Highly selective DNA oligonucleotide aptamers against aggrecanase ADAMTS5 for degenerative disc disease therapy. *Oligo 2015 Oxford: Antisense and Therapeutic Nucleic Acids*, Oxford University, United Kingdom (2015).
6. **Yu, Y.**, Chan, D., Cheah, K.S.E & Tanner, J.A. DNA aptamers can discriminate between closely related aggrecanase drug targets for degenerative disc disease therapy. *50th International Conference on Medicinal Chemistry: Interfacing Chemical Biology and Drug Discovery*, Rouen, France (2014).